Prelude Therapeutics

Oncology Therapeutics
Sponsors visas
3Open roles1 posted in 30 days
Lately:5 news stories in 90 daysFollow changes →

Facts

as of Nov 17, 2026

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients.

It is hiring: 3 open roles, 1 of them posted in the last 30 days.

Legal name
Prelude Therapeutics Inc.
Headquarters
Newark, United States
Founded
2016
Employees
201-500estimated range
Open roles
3Alion job postings
Register numbers
NAME prelude therapeutics inc
Official records
Wikidata Q138859653
Website
preludetx.com

As of Nov 17, 2026, Alion lists 3 open roles at Prelude Therapeutics. Prelude Therapeutics is headquartered in Newark, United States. It was founded in 2016. It has raised $115M in 4 funding rounds. The latest round is Venture - Series Unknown of $50M, announced in 2020.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Prelude Therapeutics Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Hiring steadily, with new roles every week.

Biotech is the largest family, 100 of open roles.

1Posted in 30 days33% of open roles are fresh
0%Remote roles0 of 3
1Hiring offices
Can they hire you from United States?by your location
Likely
3 open roles are in your country: you apply locally, no move needed.
United States3On site
Remote, from elsewhere0Rare
No posting offers visa sponsorship. Remote roles: 0.
Alion signals0-100
Demand9
Pay9
Your chance44
How badly they need people, whether they pay, how realistic getting in is.
Where the openings areshare of open roles · trend
Biotech100
Newest roles
Clinical Trial Manager
≈ $102k – $178k per year (Estimated) · In office · 7+ years exp · Bachelor's Degree · Wilmington
Associate Director, DMPK and Bioanalysis
≈ $165k – $287k per year (Estimated) · In office · 10+ years exp · Master's Degree · Wilmington
VP, Regulatory Affairs
≈ $131k – $258k per year (Estimated) · In office · 15+ years exp · Master's Degree · Wilmington
What postings ask forlanguages named in open roles
Chinese150%
Degree asked
Master's Degree 100%
2 postings state a degree.
Benefits named in postingsshare of open roles
Professional development150%
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family

Named in the work visa registers of United States.

0H-1B filings in 12 months
3Open roles in United States

In the register as Prelude Therapeutics, Inc., Wilmington, DE

Other sponsors in the same field
See 3 open roles Alert me
US Department of Labor · latest filing Mar 5, 2025

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
WilmingtonBusiest site
Loading the map
SiteTypeOpen rolesHires most forEngineering
Newark United StatesHeadquarters0
Wilmington United StatesRegional office2Biotech0%
Source: office addresses in postings and company registers

Financials

Funding rounds, investors and revenue on record.

$115MTotal raised
Venture - Series UnknownLatest round
4Rounds and grants
Money by yearUSD, rounds and grants
2020$50M1 record
2019$30M1 record
2017$30M1 record
2016$5M1 record
Sources: funding announcements, grant and company registers

Tech stack

Technologies named in job postings at Prelude Therapeutics over the last 12 months, by layer, with the share of postings for each.

4Technologies in use
2Postings analysed
53/100Stack modernity
Cloud & platformsGCP
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

Oct 72026
Blog
Ryan Holmes, Associate Director, Chemistry on behalf of the DAC team The post Precision Degrader Antibody Conjugates (DACs): An Emerging Modality in Targeted Therapeutics appeare…
Sep 232026
News · Prelude Therapeutics stock falls 9.9 percent despite FDA progress
Prelude Therapeutics stock traded at USD 4.37 on Nasdaq on September 23, 2026, while Q2 revenue reached USD 5.7 million. Q2 net loss was USD 13.9 million.
Sep 202026
News · Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial
Prelude Therapeutics stock has risen strongly in recent weeks after FDA clearance of the IND for breast cancer candidate PRT13722, with shares closing at USD 4.87 on September 18…
Sep 102026
News · YahooFinance
Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIR…
Aug 222026
News · Pulse 2.0
Prelude Therapeutics reduced its second-quarter 2026 net loss by approximately 55% year-over-year as research and development spending declined sharply following the pausing of p…
Jul 222026
Blog
Ryan Holmes, Andrew Moore, Max Foroutan, Jake Karwoski, Alex Grego, Carly Bachner1 Neha Bhagawat, Corey Basch, Soham Maity, Chun Chen, Sarah B. Pawley, Vijay Devannah, Sina Rezaz…
Sources: the outlets named on each headline, each story once